Brimonidine Compositions for Treating Erythema
The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a patient with rosacea by administering the composition of the invention to the site of erythema on the skin of the patient.
1 . A pharmaceutical composition comprising brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier selected from the group consisting of a gel and a cream.
2 . A composition according to claim 1 , wherein the brimonidine tartrate is present in an amount from about 0.175 percent by weight to about 0.185 percent by weight.
3 . A composition according to claim 1 , wherein the brimonidine tartrate is present in an amount of about 0.18 percent by weight.
4 . A composition according to claim 1 , wherein the carrier is a gel.
5 . A composition according to claim 1 , wherein the carrier is a cream.
6 . A composition according to claim 4 , wherein the gel comprises a skin-penetrating agent.
7 . A composition according to claim 6 , wherein the skin-penetrating agent is propylene glycol.
8 . A composition according to claim 4 , wherein the gel comprises a moisturizer.
9 . A composition according to claim 8 , wherein the moisturizer is glycerin.
10 . A composition according to claim 4 , wherein the gel comprises a preservative.
11 . A composition according to claim 10 , wherein the preservative is methylparaben.
12 . A composition according to claim 10 , wherein the preservative is phenoxyethanol.
13 . A composition according to claim 4 , wherein the gel comprises a sufficient amount of base to cause the carrier to have a minimum pH of about 5 and a maximum pH of about 7.5 when the gel is diluted by a factor of ten.
14 . A composition according to claim 13 , wherein the pH has a minimum of about 6.2 and a maximum of about 6.8 when the gel is diluted by a factor of ten.
15 . A composition according to claim 13 , wherein the base is sodium or potassium hydroxide.
16 . A composition according to claim 4 , wherein the gel comprises a gelling agent.
17 . A composition according to claim 16 , wherein the gelling agent is a carbomer.
18 . A composition according to claim 4 , wherein the gel comprises a protective agent, a cosmetic agent, or a combination thereof.
19 . A composition according to claim 18 , wherein the cosmetic agent is titanium dioxide.
20 . A composition according to 4 , wherein the gel comprises water, a gelling agent, a skin-penetrating agent, a moisturizer, a preservative, and a cosmetic agent.
21 . A composition according to claim 20 , wherein the gel comprises water, a carbomer, propylene glycol, glycerin, methylparaben, phenoxyethanol, glycerin, titanium dioxide and a sufficient amount of base to cause the carrier to have a minimum pH of about 6.2 and a maximum pH of about 6.8 when the gel is diluted by a factor of ten.
22 . A composition according to claim 21 , wherein the base is sodium or potassium hydroxide.
23 . A method for treating erythema in a patient with rosacea, the method comprising topically administering brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable cream or gel to the site of erythema on the skin of the patient.